ESR1 and breast cancer: Tumor suppressor MEL-18 regulates ERα activity by suppressing the SUMOylation of ERα transactivators p53 and Sp1 to promote ERα and progesterone receptor (PR) activity, and MEL-18 may be a prognostic marker and predictor of response to antihormonal therapy in breast cancer [205].